Full-Time
Confirmed live in the last 24 hours
Develops therapies for difficult-to-treat cancers
No salary listed
Mid, Senior
Boston, MA, USA + 2 more
More locations: Pennsylvania, USA | Concord, NH, USA
Candidates can reside anywhere within the East Region: Massachusetts, Pennsylvania, New Hampshire.
Syndax Pharmaceuticals develops and commercializes therapies specifically for cancer patients, focusing on challenging cases like hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer. The company conducts research and clinical trials to test the safety and effectiveness of its drugs, with the goal of bringing new treatments to market. Syndax's main product, Entinostat, is currently in clinical trials combined with Exemestane for HR+, HER2- breast cancer. Unlike many competitors, Syndax targets underserved patient populations and relies on strategic partnerships and public offerings to fund its research and development efforts. The company's goal is to advance cancer treatment by developing innovative therapies that address the needs of patients with difficult-to-treat cancers.
Company Size
201-500
Company Stage
IPO
Headquarters
Waltham, Massachusetts
Founded
2005
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Professional Development Budget
Syndax Pharmaceuticals appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer.
Syndax announces participation at the Stifel 2025 Virtual Targeted Oncology Forum.
WALTHAM, Mass., Jan. 30, 2025 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:Guggenheim SMID Cap Biotech Conference in New York, NY with a fireside chat on Thursday, February 6, 2025 , at 10:30 a.m. ETin with a fireside chat on , at Citi's 2025 Virtual Oncology Leadership Summit with a fireside chat on Wednesday, February 19, 2025 , at 9:00 a.m. ETA live webcast of the fireside chats will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.About SyndaxSyndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor
– U.S. launch expected in early February –– Niktimvo is the first and only approved treatment for chronic GVHD that targets CSF-1R to reduce the drivers of inflammation and fibrosis –– Pivotal data from the AGAVE-201 trial supporting FDA approval show treatment with Niktimvo resulted in durable responses across all organs studied and patient subgroups –WILMINGTON, Del. and WALTHAM, Mass., Jan. 15, 2025 /PRNewswire/ -- Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Niktimvo™ (axatilimab-csfr) in 9 mg and 22 mg vial sizes. The Companies expect product to be available for order in the U.S
Syndax announces presentation at 43rd Annual J.P. Morgan Healthcare Conference.